Hypertension is associated with worse cognitive function and hippocampal hypometabolism in Alzheimer's disease

European Journal of Neurology

Volumn 24, Issue 9, 2017, Pages 1173-1182

  Moonga, I ^a   Niccolini, F ^a   Wilson, H ^a   Pagano, G ^a   Politis, M ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's disease; Alzheimer's Disease Neuroimaging Initiative; blood pressure; hypertension

Indexed keywords

FLORBETAPIR F 18; GLUCOSE; ANILINE DERIVATIVE; ETHYLENE GLYCOL DERIVATIVE; FLORBETAPIR; RADIOPHARMACEUTICAL AGENT;

AGED; ALZHEIMER DISEASE; ALZHEIMERS DISEASE ASSESSMENT SCALE COGNITIVE SUBSCALE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ASSESSMENT; CLINICAL FEATURE; COGNITIVE DEFECT; CONE BEAM COMPUTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HYPERTENSION; LEFT HIPPOCAMPUS; MAJOR CLINICAL STUDY; MALE; NEUROIMAGING; NEUROLOGIC DISEASE ASSESSMENT; NEUROPSYCHIATRIC INVENTORY QUESTIONNAIRE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUESTIONNAIRE; RIGHT HIPPOCAMPUS; VERY ELDERLY; BLOOD; CEREBROSPINAL FLUID; COGNITION; COMPLICATION; COST OF ILLNESS; HIPPOCAMPUS; METABOLISM; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; POSITRON EMISSION TOMOGRAPHY; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANILINE COMPOUNDS; COGNITION; COGNITION DISORDERS; COST OF ILLNESS; ETHYLENE GLYCOLS; FEMALE; GLUCOSE; HIPPOCAMPUS; HUMANS; HYPERTENSION; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROIMAGING; NEUROPSYCHOLOGICAL TESTS; POSITRON-EMISSION TOMOGRAPHY; PSYCHIATRIC STATUS RATING SCALES; RADIOPHARMACEUTICALS;

EID: 85026413484     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.13374     Document Type: Article

References (40)

1. Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol 2011; 10: 819–828.
2. Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discovery 2011; 10: 698–712.
3. Coric V, van Dyck CH, Salloway S, et al. Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol 2012; 69: 1430–1440.
4. Doody RS, Raman R, Farlow M, et al. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med 2013; 369: 341–350.
5. Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med 2014; 370: 311–321.
6. Salloway S, Sperling R, Keren R, et al. A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. Neurology 2011; 77: 1253–1262.
7. Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 2014; 370: 322–333.
8. Galasko D, Bell J, Mancuso JY, et al. Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease. Neurology 2014; 82: 1536–1542.
9. Kivipelto M, Helkala EL, Laakso MP, et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 2001; 322: 1447–1451.
10. Luchsinger JA, Gustafson DR. Adiposity, type 2 diabetes, and Alzheimer's disease. J Alzheimer's Dis 2009; 16: 693–704.
11. Ahtiluoto S, Polvikoski T, Peltonen M, et al. Diabetes, Alzheimer disease, and vascular dementia: a population-based neuropathologic study. Neurology 2010; 75: 1195–1202.
12. Faraco G, Iadecola C. Hypertension: a harbinger of stroke and dementia. Hypertension 2013; 62: 810–817.
13. Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci 2011; 12: 723–738.
14. Qiu L, Ng G, Tan EK, Liao P, Kandiah N, Zeng L. Chronic cerebral hypoperfusion enhances Tau hyperphosphorylation and reduces autophagy in Alzheimer's disease mice. Sci Rep 2016; 6: 23964.
15. Bennett SA, Pappas BA, Stevens WD, Davidson CM, Fortin T, Chen J. Cleavage of amyloid precursor protein elicited by chronic cerebral hypoperfusion. Neurobiol Aging 2000; 21: 207–214.
16. Qiu C, Winblad B, Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol 2005; 4: 487–499.
17. DeKosky ST, Carrillo MC, Phelps C, et al. Revision of the criteria for Alzheimer's disease: a symposium. Alzheimer's Dement 2011; 7: e1–e12.
18. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003; 42: 1206–1252.
19. Teunissen CE, Petzold A, Bennett JL, et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 2009; 73: 1914–1922.
20. Freeborough PA, Fox NC. The boundary shift integral: an accurate and robust measure of cerebral volume changes from registered repeat MRI. IEEE Trans Med Imaging 1997; 16: 623–629.
21. Mosconi L, Tsui WH, De Santi S, et al. Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis. Neurology 2005; 64: 1860–1867.
22. Lowndes GJ, Saling MM, Ames D, Chiu E, Gonzalez LM, Savage GR. Recall and recognition of verbal paired associates in early Alzheimer's disease. J Int Neuropsychol Soc 2008; 14: 591–600.
23. Rousseaux M, Rénier J, Anicet L, Pasquier F, Mackowiak-Cordoliani MA. Gesture comprehension, knowledge and production in Alzheimer's disease. Eur J Neurol 2012; 19: 1037–1044.
24. van Swieten JC, Geyskes GG, Derix MM, et al. Hypertension in the elderly is associated with white matter lesions and cognitive decline. Ann Neurol 1991; 30: 825–830.
25. Obisesan TO, Obisesan OA, Martins S, et al. High blood pressure, hypertension, and high pulse pressure are associated with poorer cognitive function in persons aged 60 and older: the Third National Health and Nutrition Examination Survey. J Am Geriatr Soc 2008; 56: 501–509.
26. Bellew KM, Pigeon JG, Stang PE, Fleischman W, Gardner RM, Baker WW. Hypertension and the rate of cognitive decline in patients with dementia of the Alzheimer type. Alzheimer Dis Assoc Disord 2004; 18: 208–213.
27. Launer LJ, Ross GW, Petrovitch H, et al. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging 2000; 21: 49–55.
28. Wu C, Zhou D, Wen C, Zhang L, Como P, Qiao Y. Relationship between blood pressure and Alzheimer's disease in Linxian County, China. Life Sci 2003; 72: 1125–1133.
29. Skoog I, Lernfelt B, Landahl S, et al. 15-year longitudinal study of blood pressure and dementia. Lancet 1996; 347: 1141–1145.
30. Kalaria RN, Akinyemi R, Ihara M. Does vascular pathology contribute to Alzheimer changes? J Neurol Sci 2012; 322: 141–147.
31. Treiber KA, Lyketsos CG, Corcoran C, et al. Vascular factors and risk for neuropsychiatric symptoms in Alzheimer's disease: the Cache County Study. Int Psychogeriatr 2008; 20: 538–553.
32. Jutkowitz E, MacLehose RF, Gaugler JE, Dowd B, Kuntz KM, Kane RL. Risk factors associated with cognitive, functional, and behavioral trajectories of newly diagnosed dementia patients. J Gerontol A Biol Sci Med Sci 2017; 72: 251–258.
33. Lopez OL, Smith G, Becker JT, Meltzer CC, DeKosky ST. The psychotic phenomenon in probable Alzheimer's disease: a positron emission tomography study. J Neuropsychiatry Clin Neurosci 2001; 13: 50–55.
34. Kato T, Inui Y, Nakamura A, Ito K. Brain fluorodeoxyglucose (FDG) PET in dementia. Ageing Res Rev 2016; 30: 73–84.
35. Hanseeuw BJ, Schultz AP, Betensky RA, Sperling RA, Johnson KA. Decreased hippocampal metabolism in high-amyloid mild cognitive impairment. Alzheimer's Dement 2016; 12: 1288–1296.
36. Sánchez-Catasús CA, Stormezand GN, van Laar PJ, De Deyn PP, Sánchez MA, Dierckx RA. FDG-PET for prediction of AD dementia in mild cognitive impairment. A review of the state of the art with particular emphasis on the comparison with other neuroimaging modalities (MRI and Perfusion SPECT). Curr Alzheimer Res 2017; 14: 127–142.
37. Hughes TM, Craft S, Lopez OL. Review of the potential role of arterial stiffness in the pathogenesis of Alzheimer's disease. Neurodegener Dis Manag 2015; 5: 121–135.
38. Weller RO, Boche D, Nicoll JA. Microvasculature changes and cerebral amyloid angiopathy in Alzheimer's disease and their potential impact on therapy. Acta Neuropathol 2009; 118: 87–102.
39. Salerno JA, Murphy DG, Horwitz B, et al. Brain atrophy in hypertension. A volumetric magnetic resonance imaging study. Hypertension 1992; 20: 340–348.
40. Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 2013; 9: 106–118.